Graph Therapeutics, a next-generation techbio company developing precision medicinesfor inflammatory and immune-mediated diseases, has secured a new $5 millioninvestment led by Daphni, the Paris-based...

Source: Tech.eu — read the full report at the original publisher.

This is a curated wire item. The Continuum Brief does not republish full third-party articles; this entry links to the original source.